German Hodgkin's Lymphoma Study Group trials: Lessons from the past and current strategies

Clinical Lymphoma and Myeloma

Volumn 6, Issue 6, 2006, Pages 458-468

  Draube, Andreas ^a   Behringer, Karolin ^a   Diehl, Volker ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chemotherapy; Combination therapy; Cotswald's staging classification; Prognostic factors

Indexed keywords

BLEOMYCIN; CD30 ANTIGEN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LOMUSTINE; MDX 060; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; PREDNISONE; PROCARBAZINE; SGN 30; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RELAPSE; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; GERMANY; HODGKIN DISEASE; HUMAN; LEUKEMIA; MYELODYSPLASTIC SYNDROME; PROGNOSIS; REVIEW; RISK ASSESSMENT; SECOND CANCER; STANDARD; TREATMENT PLANNING;

EID: 33745879434     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.026     Document Type: Review

References (70)

1. DeVita VJ, Hubbard SM. Hodgkin's disease. N Engl J Med 1993; 328:560-565.
2. Diehl V. Chemotherapy or combined modality treatment: the optimal treatment for Hodgkin's disease. J Clin Oncol 2004; 22:15-18.
3. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21:3431-3439.
4. Duhmke E, Franklin J, Pfreundschuh M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001; 19:2905-2914.
5. Sieber M, Franklin J, Tesch H, et al. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: results of the German Hodgkin's Lymphoma Study Group (GHSG) trial HD7. Blood 2002; 100:93a (Abstract #341).
6. Diehl V, Brillant C, Engert A, et al. Reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: interim analysis of the HD 10 trial of the GHSG. Eur J Haematol 2004; 73(suppl 65):37 (Abstract #E03).
7. Diehl V, Pfreundschuh M, Loffler M, et al. Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group. Med Oncol Tumor Pharmacother 1989; 6:155-162.
8. Sieber M, Tesch H, Pfistner B, et al. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group trial HD5. J Clin Oncol 2002; 20:476-484.
9. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21:3601-3608.
10. Diehl V, Brillant C, Engert A, et al. Intensification of chemotherapy and concomitant reduction of radiotherapy dose in intermediate stage Hodgkin's lymphoma: results of the fourth interim analysis of the HD 11 trial of the GHSG. Eur J Haematol 2004; 73(suppl 65):37 (Abstract #E02).
11. Sieber M, Tesch H, Pfistner B, et al. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol 2004; 15:276-282.
12. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386-2395.
13. Diehl V, Brillant C, Franklin J, et al. BEACOPP Chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD12- trials of the German Hodgkin Study Group (GHSG). Blood 2004; 104:91a (Abstract #307).
14. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-1514.
15. Lister T, Crowther D, Sutcliffe S, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting [published erratum in J Clin Oncol 1990; 8:1602]. J Clin Oncol 1989; 7:1630-1636.
16. Horning S, Hoppe R, Hancock S, Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 1988; 6:1822-1831.
17. Radford J, Cowen R, Ryder W. Four weeks of neo-adjuvant chemotherapy significantly reduces the progression rate in patients treated with limited field radiotherapy for clinical stage (CS IA/IIA) Hodgkin's disease. Results of a randomized pilot. Ann Oncol 1996; 7:66.
18. Noordijk E, Carde P, Hagenbeek A. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease. Six-year results of the EORTC-GPMC controlled clinical trials 'H7-VF,' 'H7-F' and 'H7-U'. Int J Radiat Oncol Biol Phys 1997; 39(2 suppl 1):173.
19. Bonfante V, Viviani S, Devizzi L, et al. Ten-years experience with ABVD plus radiotherapy: subtotal nodal (STNI) vs involved field (IFRT) in early-stage Hodgkin's disease (Hd). Proc Am Soc Clin Oncol 2001; 20:281a (Abstract #1120).
20. Meyer RM. Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphomia? Eur J Haematol Suppl 2005:115-120.
21. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:4634-4642.
22. DeVita VJ, Simon RM, Hubbard SM. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92:587-595.
23. Longo D, Young R, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4:1295-1306.
24. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36:252-259.
25. Santoro A, Bonadonna G, Valagussa P. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5:27-37.
26. Canellos G, Anderson J, Propert K, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478-1484.
27. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002; 346:1417-1418.
28. Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy - comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15:1638-1645.
29. Glick JH, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998; 16:19-26.
30. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21:607-614.
31. Diehl V. Advanced Hodgkin's disease: ABVD is better, yet is not good enough! J Clin Oncol 2003; 21:583-585.
32. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20:630-637.
33. Horning SJ, Hoppe RT, Advani R, et al. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: mature data in early and advanced stage patients. Blood 2004; 104:92a (Abstract #308).
34. Chisesi T, Federico M, Levis A, et al. ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol 2002; 13(suppl 1):102-106.
35. Federico M, Levis A, Luminari S, et al. ABVD vs. STANFORD V (SV) vs. MOPP-EBV-CAD (MEC) in advanced Hodgkin's lymphoma. Final results of the IIL HD9601 randomized trial. Proc Am Soc Clin Oncol 2004; 23:557 (Abstract #6507).
36. Radford JA, Rohatiner AZ, Ryder WD, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002; 20:2988-2994.
37. Diehl V. Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG). Ann Hematol 1993; 66:139-140.
38. Diehl V, Sieber M, Ruffer U, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997; 8:143-148.
39. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998; 16:818-829.
40. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348:2396-2406.
41. Sieber M, Bredenfeld H, Josting A, et al. 14-Day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21:1734-1739.
42. Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98:2930-2934.
43. Guay C, Lepine M, Verreault J, et al. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003; 44:1225-1231.
44. Spaepen K, Stroobants S, Verhoef G, et al. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003; 30(suppl 1):97-105.
45. Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96:1280-1286.
46. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2002; 20:221-230.
47. Josting A, Katay I, Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 1998; 9:289-295.
48. Canellos GP. Treatment of relapsed Hodgkin's disease: strategies and prognostic factors. Ann Oncol 1998; 9(suppl 5):91-96.
49. Brice P, Divine M, Simon D, et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol 1999; 10:1485-1488.
50. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16:2817-2824.
51. Dean RM, Bishop MR. Allogeneic hematopoietic stem cell transplantation for lymphoma. Clin Lymphoma 2004; 4:238-249.
52. Fisher R, De VV, Hubbard S, et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979; 90:761-763.
53. Longo D, Duffey P, Young R, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10:210-218.
54. Bierman P, Bagin R, Jagannath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993; 4:767-773.
55. Reece D, Connors J, Spinelli J, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83:1193-1199.
56. Gribben JG, Linch DC, Singer CR, et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73:340-344.
57. Armitage JO, Bierman PJ, Vose JM, et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 1991; 91:605-611.
58. Linch D, Winfield D, Goldstone A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341:1051-1054.
59. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359:2065-2071.
60. Schmitz N, Haverkamp H, Josting A, et al. Long-term results of HD-R1: conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoetic stem cell transplantation in relapsed Hodgkin's disease. Eur J Haematol 2004; 73(suppl 65):R16.
61. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/ cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002; 13:1628-1635.
62. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma - results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Blood 2003; 104:309 (Abstract #1461).
63. Porter DL, Stadtmauer EA, Lazarus HM. 'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning. Bone Marrow Transplant 2003; 31:739-746.
64. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31:667-678.
65. Schmitz N, Sureda A. The role of allogeneic stem-cell transplantation in Hodgkin's disease. Eur J Haematol Suppl 2005:146-149.
66. Schnell R, Borchmann P, Staak JO, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003; 14:729-736.
67. Vriesendorp HM, Quadri SM, Wyllie CT, et al. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin Cancer Res 1999; 5:3324-3329.
68. Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005; 23:4669-4678.
69. Bartlett NL, Bernstein SH, Leonard JP, et al. Safety, antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2003; 102:647a (Abstract #2390).
70. Ansell S, Byrd J, Horwitz S, et al. Phase I/II study of a fully human anti-CD30 monoclonal antibody (MDX-060) in Hodgkins disease (HD) and anaplastic large cell lymphoma (ALCL). Blood 2003; 102:181a (Abstract #632).